Dominari (NASDAQ:DOMH) Shares Down 4.6% – Here’s Why

Dominari Holdings Inc. (NASDAQ:DOMH)’s share price dropped 4.6% on Monday . The company traded as low as $3.23 and last traded at $3.30. Approximately 82,365 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 115,770 shares. The stock had previously closed at $3.46.

Analysts Set New Price Targets

DOMH has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of Dominari from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, January 12th. Wall Street Zen lowered shares of Dominari from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Dominari currently has a consensus rating of “Sell”.

Dominari Stock Performance

The firm has a market capitalization of $53.53 million, a PE ratio of 0.59 and a beta of 0.74. The firm’s 50-day moving average is $4.12 and its 200 day moving average is $5.13.

Dominari Announces Dividend

The business also recently declared a dividend, which was paid on Monday, January 26th. Shareholders of record on Monday, January 5th were given a dividend of $0.445 per share. The ex-dividend date of this dividend was Monday, January 5th.

Insider Buying and Selling at Dominari

In other news, COO Christopher Franklin Devall sold 140,000 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $3.82, for a total value of $534,800.00. Following the sale, the chief operating officer directly owned 190,702 shares in the company, valued at $728,481.64. This represents a 42.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 225,000 shares of company stock valued at $876,850 over the last ninety days. Insiders own 55.30% of the company’s stock.

Hedge Funds Weigh In On Dominari

A number of institutional investors have recently modified their holdings of DOMH. Creek Drive Management Group LLC acquired a new stake in Dominari during the fourth quarter worth approximately $1,861,000. NewEdge Advisors LLC acquired a new stake in shares of Dominari during the fourth quarter worth $50,000. Oxford Asset Management LLP acquired a new stake in shares of Dominari during the fourth quarter worth $120,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Dominari in the fourth quarter valued at $96,000. Finally, Susquehanna Advisors Group Inc. acquired a new position in Dominari in the fourth quarter valued at $182,000. Institutional investors and hedge funds own 42.48% of the company’s stock.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.